Search alternatives:
significant potential » significant positive (Expand Search)
potential decrease » substantial decrease (Expand Search)
largest decrease » largest decreases (Expand Search), marked decrease (Expand Search)
larger decrease » marked decrease (Expand Search)
Showing 61 - 80 results of 24,748 for search '(( significant potential decrease ) OR ( significantly ((largest decrease) OR (larger decrease)) ))', query time: 1.67s Refine Results
  1. 61
    <i>Lp</i> knockdown significantly impairs oogenesis and affects Vg localization.

    <i>Lp</i> knockdown significantly impairs oogenesis and affects Vg localization. by Iryna Stryapunina (17867390)

    Published 2024
    Save to List
    Saved in:
  2. 62
    Significantly Enriched Pathways.

    Significantly Enriched Pathways. by Jiyong Zhang (2498740)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  3. 63
    Significant relationships between QOL measures on infusion day and day 7.

    Significant relationships between QOL measures on infusion day and day 7. by Jordan K. Abbott (8934239)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  4. 64
    Phase 2 significant effects.

    Phase 2 significant effects. by Wendy C. Crone (2262169)

    Published 2023
    Save to List
    Saved in:
  5. 65
    Phase 1 significant effects.

    Phase 1 significant effects. by Wendy C. Crone (2262169)

    Published 2023
    Save to List
    Saved in:
  6. 66
    Sensitivity analyses of seroprevalence with the largest sample size study omitted.

    Sensitivity analyses of seroprevalence with the largest sample size study omitted. by Yu Zhou (89766)

    Published 2024
    Save to List
    Saved in:
  7. 67
    Ordination of butterfly community composition change through time.

    Ordination of butterfly community composition change through time. by Nicole B. Kucherov (11558817)

    Published 2021
    Subjects:
    Save to List
    Saved in:
  8. 68
    The impact of different osmotic potentials on percentage decrease in their seed germination and growth traits under different osmotic potentials.

    The impact of different osmotic potentials on percentage decrease in their seed germination and growth traits under different osmotic potentials. by Shahzadi Mahpara (10196689)

    Published 2022
    Save to List
    Saved in:
  9. 69
    CBP per cumulative year for daratumumab and pembrolizumab per vial.

    CBP per cumulative year for daratumumab and pembrolizumab per vial. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  10. 70
    S4 Fig -

    S4 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  11. 71
    S1 Fig -

    S1 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  12. 72
    S5 Fig -

    S5 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  13. 73
    Scenario analysis for pembrolizumab using a cumulative cost-based price per year per vial.

    Scenario analysis for pembrolizumab using a cumulative cost-based price per year per vial. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  14. 74
    S3 Fig -

    S3 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  15. 75
    S6 Fig -

    S6 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  16. 76
    CBP per cumulative indication for daratumumab and pembrolizumab per vial.

    CBP per cumulative indication for daratumumab and pembrolizumab per vial. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  17. 77
    Inputs utilized in base-case and scenario analysis for daratumumab and pembrolizumab, both unadjusted and adjusted for PPP and inflation.

    Inputs utilized in base-case and scenario analysis for daratumumab and pembrolizumab, both unadjusted and adjusted for PPP and inflation. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  18. 78
    Implementation of indication-based pricing (10<sup>th</sup> scenario) for daratumumab and pembrolizumab.

    Implementation of indication-based pricing (10<sup>th</sup> scenario) for daratumumab and pembrolizumab. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  19. 79
    Scenario analysis for daratumumab using a cumulative cost-based price per year per vial.

    Scenario analysis for daratumumab using a cumulative cost-based price per year per vial. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  20. 80
    Input parameters for the base-case analysis.

    Input parameters for the base-case analysis. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:

Search Tools: